Rectum malignant melanoma

Summary

Rectum malignant melanoma (MONDO:0002167) is a cancer and 1 clinical trial. Top therapeutic interventions include cabozantinib. A subtype of rectal cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	rectum malignant melanoma
Mondo ID	MONDO:0002167
DOID	DOID:1992
NCIT	C4640
SNOMED CT	276822007
UMLS	C0349539
MedGen	87605
Anatomy (UBERON)	UBERON:0001052
Is cancer (heuristic)	yes

Also known as: malignant melanoma of rectum · malignant melanoma of the rectum · melanoma (disease) of rectum · melanoma of rectum · melanoma of the rectum · rectal malignant melanoma · rectal melanoma · rectum melanoma · rectum melanoma (disease)

Data availability: 1 cell line.

Disease family

This is a subtype of rectal cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › intestinal disorder › large intestine disorder › rectal disorder › rectal neoplasm › rectal cancer › rectum malignant melanoma

Related subtypes (5): anus cancer, rectum lymphoma, rectum sarcoma, rectosigmoid junction cancer, rectal carcinoma

Subtypes (1): anal melanoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05111574	PHASE2	RECRUITING	Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CABOZANTINIB	4	3